AI assistant
Werewolf Therapeutics, Inc. — Director's Dealing 2021
Apr 29, 2021
34192_dirs_2021-04-29_8901a0d2-01b4-456c-a33c-decd334e759c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2021-04-29
Reporting Person: GADICKE ANSBERT (10% Owner)
Reporting Person: MPM ONCOLOGY INNOVATIONS FUND LP (10% Owner)
Reporting Person: UBS Oncology Impact Fund L.P. (10% Owner)
Reporting Person: Oncology Impact Fund (Cayman) Management L.P. (10% Owner)
Reporting Person: MPM Oncology Impact Management LP (10% Owner)
Reporting Person: MPM Oncology Innovations Fund GP LLC (10% Owner)
Reporting Person: MPM Oncology Impact Management GP LLC (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 461408 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $ | Common Stock (4477742) | Indirect | ||
| Series B Preferred Stock | $ | Common Stock (1488033) | Indirect | ||
| Warrant (Right to Buy) | $0.09 | 2024-12-05 | Common Stock (8031) | Indirect | |
| Warrant (Right to Buy) | $0.09 | 2025-04-09 | Common Stock (8031) | Indirect | |
| Warrant (Right to Buy) | $0.09 | 2025-08-13 | Common Stock (42842) | Indirect |
Footnotes
F1: The shares are held by MPM Asset Management LLC ("AM LLC"). Ansbert Gadicke is a member of AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F2: Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
F3: The shares are held as follows: 2,087,358 by MPM BioVentures 2014, L.P. ("BV 2014"), 139,224 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,848 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 457,643 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 1,721,669 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a member of BV LLC. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a manager of MPM OIF GP. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC.
F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5: The shares are held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B), 23,876 by AM BV2014, 152,083 by MPM OIF and 572,141 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F6: Immediately exercisable.
F7: The warrants are held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV2014 and 4,016 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F8: The warrants are held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV2014, 5,355 by MPM OIF and 18,744 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.